Search form
Search
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Menu
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye
ThromboGenics R&D Investor Meeting on Novel Disease-Modifiying Approaches for Diabetic Eye Disease
Watch webcast replay: